Analysis in progress
Initialising…
0%
complete
This report is still being assembled — sections appear as each stage finishes. It isn't final yet.
PPP2R1A
Final classification
VUS
PPP2R1A c.739A>G · p.Thr247Ala
PPP2R1A

NM_014225.5:c.739A>G (p.Thr247Ala) is a missense variant in exon 6 of PPP2R1A, a gene associated with autosomal dominant Houge-Janssens syndrome type 2 (neurodevelopmental disorder). PVS1 is not applicable as this is a missense variant that does not fall into null-variant categories.

Gene
PPP2R1A
Transcript
NM_014225.5
HGVS · transcript:coding
NM_014225.5:c.739A>G
Consequence
N/A
GRCh38
chr19:52213042 A>G
GRCh37
chr19:52716295 A>G
Basis gene-specific framework lacked a usable explicit final combination framework, so generic ACMG/AMP 2015 final-combination rules were applied as fallback; applied criteria: PM2 supporting, BP4 supporting; combination = 1 supporting + 1 supporting benign, which maps to VUS.
gene-specific framework lacked a usable explicit final combination framework, so generic ACMG/AMP 2015 final-combination rules were applied as fallback; applied criteria: PM2 supporting, BP4 supporting; combination = 1 supporting + 1 supporting benign, which maps to VUS.
Classification rationale
PM2 BP4 VUS
PPP2R1A c.739A>G

NM_014225.5:c.739A>G (p.Thr247Ala) is a missense variant in exon 6 of PPP2R1A, a gene associated with autosomal dominant Houge-Janssens syndrome type 2 (neurodevelopmental disorder). PVS1 is not applicable as this is a missense variant that does not fall into null-variant categories.1 This variant is absent from gnomAD v2.1 and gnomAD-Canada, and is present at an extremely low frequency in gnomAD v4.1 (1/1,610,866 alleles; AF = 6.21 × 10⁻⁷), satisfying PM2 at supporting strength.2 Multiple in silico predictors do not support a deleterious effect: REVEL score is 0.285 (below pathogenic threshold of 0.5), BayesDel score is −0.185 (predicted benign), and SpliceAI predicts no splicing impact (max delta = 0.00), satisfying BP4 at supporting strength.3 No variant-specific functional studies, de novo reports, case-control data, segregation data, or ClinVar classifications exist for this variant. No pathogenic comparator variant at the same codon or residue has been identified. All remaining criteria are not met or not applicable.4 The only applicable criteria are PM2_supporting and BP4_supporting, which carry equal and opposite weight. Under the generic ACMG/AMP 2015 combination rules (PMID:25741868), one supporting pathogenic criterion and one supporting benign criterion cancel each other, resulting in a classification of Variant of Uncertain Significance (VUS).5

PM2 + BP4 VUS
Gene diagram · NM_014225.5 · variants mapped to exon structure
PPP2R1A NM_014225.5
Fetching transcript structure from UCSC…
Applied criteria · 2 applied · 21 assessed
Applied · 2
Strength Supporting Moderate Strong Very strong
PM2 supporting Pathogenic
This variant is absent from gnomAD v2.1 and gnomAD-Canada v1.0, and present at an extremely low allele frequency in gnomAD v4.1 (1/1,610,866 alleles; AF = 6.21 × 10⁻⁷, 0.00006%), well below the 0.1% PM2 threshold for a rare variant absent from population databases. This constitutes PM2 at supporting strength.
Absent from gnomAD v2.1 (0 alleles).gnomAD v4.1: 1/1610
BP4 supporting Benign
Multiple lines of computational evidence suggest no impact on the gene product. REVEL score is 0.285 (below commonly used pathogenic threshold of 0.5), BayesDel score is -0.184741 (negative, predicted benign), and SpliceAI predicts no splicing alteration (max delta = 0.00). All three in silico predictors are concordant in not supporting a deleterious effect.
REVEL 0.285 (below 0.5 pathogenic threshold).BayesDel -0.184741 (predicted benign).SpliceAI max delta 0.00 (no splicing impact).
Assessed · not applied
Pathogenic
PS1 No same-amino-acid change (Thr247Ala or T247A) has been reported as pathogenic via a different nucleotide change in ClinVar or the literature.
PS2 No de novo occurrence with confirmed parentage has been reported for NM_014225.5:c.739A>G.
PS3 No variant-specific functional assays (e.g., PP2A phosphatase activity, substrate binding, or HEAT repeat structural integrity) have been performed for p.Thr247Ala.
PS4 The variant is extremely rare (1/1,610,866 alleles in gnomAD v4.1).
PM1 Residue Thr247 lies within HEAT repeat 6 of the PPP2R1A scaffold domain, a functionally important region for PP2A holoenzyme assembly.
PM5 No pathogenic missense variant at the same amino acid residue (Thr247) has been identified in ClinVar.
PM6 No de novo observation (even without confirmed parentage) has been reported for NM_014225.5:c.739A>G.
PP1 No families with multiple affected individuals segregating this variant have been published.
PP2 While PPP2R1A is an autosomal dominant neurodevelopmental disorder gene in which missense variants are a known mechanism, PP2 additionally requires demonstration of a low rate of benign missense variation in the gene.
PP3 Multiple in silico prediction tools do not support a deleterious effect.
PP4 No clinical phenotype information for the proband is available for assessment.
PP5 The variant is absent from ClinVar.
Benign
BA1 The variant is not a common polymorphism.
BS1 The variant allele frequency in gnomAD v4.1 (6.21 × 10⁻⁷, 0.00006%) is far below the 0.3% BS1 threshold for a variant too common to cause a dominant fully penetrant disorder.
BS2 No homozygous observation of this variant has been reported in any population database.
BS3 No well-established in vitro or in vivo functional studies demonstrate that p.Thr247Ala does not affect protein function.
BS4 No segregation data are available in affected families.
BP1 BP1 applies when a missense variant occurs in a gene for which only truncating variants cause disease.
BP2 The variant has not been observed in trans with a known pathogenic PPP2R1A variant.
BP5 BP5 requires a reputable source to have classified the variant as benign or to have found an alternative molecular basis for disease in a case.
BP6 The variant is absent from ClinVar.
N/A · 5 PVS1 · PM3 · PM4 · BP3 · BP7
Research & evidence
Population frequency
gnomAD v4.1 screenshot
gnomAD v4.1
gnomAD v2.1 screenshot
gnomAD v2.1
v4.1
This variant is present in gnomAD v4.1 (AF= 6.20784e-07; MAF= 0.00006%, 1/1610866 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 8.47936e-07; MAF= 0.00008%, 1/1179334 alleles, homozygotes = 0).
v2.1
Absent from gnomAD v2.1.
🇨🇦 CA
Absent from gnomAD-Canada v1.0.
Allele frequency by ancestry
three datasets · side by side
gnomAD v4.1
6.2e-05% · 1 / 1,610,866
0 hom
European (non-Finnish)
1 / 1,179,334
8.5e-05%
+ 9 not observed (Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American)
gnomAD v2.1
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
gnomAD Canada 🇨🇦
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar screenshot
ClinVar
This variant is absent from ClinVar.
SpliceAI screenshot
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.285. BayesDel score = -0.184741.
Functional / OncoKB screenshot
Functional Unknown Oncogenic Effect
OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. PPP2R1A encodes a serine/threonine phosphatase that regulates cell growth and division. PPP2R1A is frequently mutated in endometrial and ovarian cance
OncoKB ↗
COSMIC screenshot
COSMIC
Cancer hotspots screenshot
Cancer hotspots
Somatic evidence Not in COSMIC / hotspots
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).
Hotspots
This variant does not lie in a statistically significant hotspot.
Sources & reference links
8Sources
ClinVar
gnomAD v2.1
gnomAD v4.1
gnomAD-Canada
SpliceAI
OncoKB
COSMIC
Cancer hotspots